Physician profile
Ingrid Grafals
NPI 1538122262
$11,729.72
in general payments reported to CMS, 2019-2025
42 companies · $1,966 in 2025
The $1,966 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,162 · 2020: $1,847 · 2021: $2,618 · 2022: $1,415 · 2023: $859 · 2024: $1,863 · 2025: $1,966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,582 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,582.47 |
| Education | $105.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,917.82 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $1,430.46 | 2019-2025 | |
| Novo Nordisk INC | $1,341.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $924.06 | 2019-2025 | |
| Lilly USA, LLC | $841.08 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $701.57 | 2019-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $477.54 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $416.19 | 2019-2023 | Evenity, Prolia |
| Astellas Pharma US INC | $376.80 | 2019-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $368.06 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $332.81 | 2019-2022 | |
| Baxter Healthcare | $328.62 | 2022 | |
| Welch Allyn | $328.62 | 2021 | |
| Janssen Pharmaceuticals, INC | $266.35 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $179.89 | 2019-2022 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $178.77 | 2023-2025 | Cologuard Collection Kit |
| Allergan, INC. | $176.88 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $157.22 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $134.20 | 2024-2025 | Unithroid |
| Eisai INC. | $129.77 | 2020-2021 | |
| Ibsa Pharma INC. | $106.65 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $97.12 | 2020-2025 | |
| Sumitomo Pharma America, INC. | $76.52 | 2023-2025 | Gemtesa |
| Avanir Pharmaceuticals, INC. | $55.45 | 2019 | |
| Boston Scientific Corporation | $34.44 | 2025 | Watchman Access System |
| Sanofi Pasteur INC. | $31.36 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $27.17 | 2020-2021 | |
| Inspire Medical Systems, INC. | $26.42 | 2024 | Inspire |
| Corcept Therapeutics | $24.13 | 2021 | |
| Intra-Sana Laboratories | $23.17 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Shire North American Group INC | $22.54 | 2019 | |
| Seqirus USA INC | $21.22 | 2025 | Flucelvax, Fluad |
| Insightec,INC | $20.82 | 2025 | Exablate |
| Duchesnay USA Incorporated | $20.19 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $19.88 | 2025 | |
| Echosens North America, INC. | $19.34 | 2025 | Fibroscan |
| Bausch Health US, LLC | $19.06 | 2022 | |
| Circassia INC. | $17.80 | 2020 | |
| Currax Pharmaceuticals LLC | $16.67 | 2023 | Contrave, Onzetra Xsail |
| Medtronic, INC. | $14.90 | 2024 | Closurefast |
| Dermira, INC. | $14.72 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $12.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ingrid Grafals listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.